Breaking news

Christmas BPS

A paper entitled “PN6047, a G protein-biased delta opioid receptor agonist with an improved therapeutic profile for use in chronic pain” was delivered at the Christmas meeting of the British Pharmacological Society at London’s QE2 Centre (17–20th December). The communication was given by Dr Alex Conibear who is working in Prof Eamonn Kelly’s research group at the University of Bristol funded by a Medical Research Council project grant to PharmNovo and Prof Kelly for the study of biased signalling via delta opioid receptors. The potential clinical use of PN6047 for the treatment of chronic pain and, in particular, mechanical allodynia, was explained and a detailed account of its biased signalling profile was given.

Read more →

A key step

PharmNovo AB have been granted a patent in the USA for our candidate delta opioid receptor agonist PN6047. The European Patent Office is very likely to follow suit early in 2019. PN6047 is a biased delta opioid receptor agonist (DOBRA) favouring signalling through G proteins and, in preclinical testing, it has none of the unwanted side effects of conventional opioid analgesics.PharmNovo AB have been granted a patent in the USA for our candidate delta opioid receptor agonist PN6047. This is a key step towards clinical testing for the treatment of chronic pain states.

Read more →

Medicon Village Office

In November, PharmNovo AB opened a new office at the Medicon Village in Lund, Sweden. This science research park is a transformation of former Astra Zeneca buildings now housing over 100 high tec organizations. The location provides extensive opportunities for collaborations at every level of drug development from molecular design to clinical testing.

Read more →

Joint work in Liverpool

PharmNovo and the School of Pharmacy and Biomedical Sciences at Liverpool John Moores University are collaborating to produce novel nasally delivered small peptide antagonists of the calcitonin gene related peptide (CGRP) receptor for the treatment of migraine. The team has been boosted with the engagement of a new PhD student Vera D’Aloiso who will be working with Dr Chris Coxon and Prof Gillian Hutcheon on the synthesis and formulation of the peptides. The collaboration has been funded by a feasibility study grant from Innovate UK.

Read more →

Clinical Potential

In order to provide advice on the clinical potential for PharmNovo’s delta opioid receptor agonists, Professor Andrew Rice from Imperial College London has agreed to become a consultant to the team. Prof Rice is an internationally regarded clinical and scientific expert in the field of chronic pain.

Read more →

Find us

PharmNovo AB
Medicon Village AB
Scheelevägen 6
SE-223 81 Lund, Sweden